Two new analyses suggest bariatric surgery may reduce the risk of several obesity-related cancers, including endometrial, liver, and colorectal — but experts are urging caution. Both studies relied on observational data with notable methodological limitations, and one meta-analysis drew criticism for mixing surgery and drug comparisons in the same pooled estimates. Bottom line: weight-loss surgery shouldn't be recommended as a cancer-prevention tool just yet.
Two recent analyses add to the growing body of evidence linking bariatric surgery to a lower risk of obesity-related cancers — but experts say the data is far from ready to change clinical practice. A systematic review and meta-analysis found bariatric surgery associated with reduced incidence of breast, endometrial, and colorectal cancers, while a large Nordic cohort study of over 784,000 patients reported significant reductions in liver, endometrial, and ovarian cancers. Both studies, however, were observational in design, making it impossible to establish cause and effect.
The meta-analysis drew particular scrutiny. Critics noted that it combined comparisons of bariatric surgery, semaglutide, and tirzepatide against DPP-4 inhibitors — making it difficult to draw conclusions specifically about surgery. Discrepancies between the abstract and main text figures went unexplained, and the paper was accepted just seven days after submission, raising peer-review concerns. The Nordic study, while larger and more rigorous, still lacked data on BMI, smoking, and lifestyle factors.
Key Takeaways:
Why it matters: As obesity rates climb and GLP-1 drugs reshape weight management, clinicians and patients are eager for data on long-term cancer benefits. These studies hint at real associations, but the methodological gaps mean bariatric surgery cannot yet be recommended as a cancer-prevention strategy.
